Resumo

MINARDI, EP. Miastenia gravis secondary to pembrolizumab. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.2, pp.145-146.  Epub 15-Mar-2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000200015.

In recent years the development of anti-cancer target drugs therapy has been increasing exponentially. In this context, a monoclonal antibody group's which inhibits the programmed cell death 1 receptor, has emerged as an effective frontline of treatment of certain neoplasms. Pembrolizumab, a humanized monoclonal antibody, is a standard option for the treatment of advanced and metastatic malignancies like multiple myeloma. However, clinical research has uncovered diverse, unpredictable and serious immune related adverse events that raise concerns regarding it's safety. Here we describe the case of an oncology patient with a suspected myasthenia gravis after receiving pembrolizumab 200 mg every 3 weeks.

Palavras-chave : Myasthenia gravis; pembrolizumab; programmed cell death 1 receptor.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )